Irritable Bowel Syndrome and Female Patients

Gastroenterology Clinics of North America

Volumn 45, Issue 2, 2016, Pages 179-204

  Harris, Lucinda A ^a   Umar, Sarah B ^a   Baffy, Noemi ^a   Heitkemper, Margaret M ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Constipation; Diarrhea; Diet; Female gender; Irritable bowel syndrome; Treatment

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ATROPINE PLUS DIPHENOXYLATE; BISACODYL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; DICYCLOVERINE; DIGESTIVE TRACT AGENT; ELUXADOLINE; ESTROGEN; HYOSCYAMINE; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; MACROGOL 3350; NORADRENALIN UPTAKE INHIBITOR; OBETICHOLIC ACID; ONDANSETRON; PEPPERMINT OIL; PLACEBO; PROBIOTIC AGENT; PROGESTERONE; PRUCALOPRIDE; RIFAXIMIN; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; TIROPRAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ANTIDIARRHEAL AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GASTROINTESTINAL AGENT; LAXATIVE; OLIGOSACCHARIDE;

ABDOMINAL PAIN; ALTERNATIVE MEDICINE; CARBOHYDRATE DIET; CHRONIC CONSTIPATION; COGNITIVE BEHAVIORAL THERAPY; COLONOSCOPY; COLORECTAL CANCER; CONSTIPATION; CROHN DISEASE; DIARRHEA; DIET RESTRICTION; DIETARY FIBER; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG WITHDRAWAL; EXERCISE; FEMALE; FERMENTED PRODUCT; GLUTEN FREE DIET; HEADACHE; HEART DISEASE; HUMAN; HYPNOSIS; IRRITABLE COLON; ISCHEMIC COLITIS; NAUSEA; PATHOPHYSIOLOGY; PELVIC FLOOR DISORDER; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEX DIFFERENCE; SLEEP; SYMPTOMATOLOGY; ULCERATIVE COLITIS; VATER PAPILLA STENOSIS; WOMEN'S HEALTH; COMPLICATION; DIET THERAPY; DOCTOR PATIENT RELATION; FERMENTATION; IRRITABLE BOWEL SYNDROME; KINESIOTHERAPY; THERAPEUTIC USE;

ABDOMINAL PAIN; ANTIDIARRHEALS; CONSTIPATION; DIARRHEA; DIET THERAPY; DIET, GLUTEN-FREE; DIETARY FIBER; EXERCISE THERAPY; FEMALE; FERMENTATION; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; LAXATIVES; OLIGOSACCHARIDES; PARASYMPATHOLYTICS; PHYSICIAN-PATIENT RELATIONS; SLEEP; WOMEN;

EID: 84977147407     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2016.02.001     Document Type: Review

References (130)

1. Chial H.J., Camilleri M. Gender differences in irritable bowel syndrome. J Gend Specif Med 2002, 5:37-45.
2. Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012, 10:712-721.
3. Lovell R.M., Ford A.C. Effect of gender on the prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012, 107(7):991-1000.
4. Maguen S., Madden E., Cohen B., et al. Association of mental health problems with gastrointestinal disorders in Iraq and Afghanistan veterans. Depress Anxiety 2014, 31:160-165.
5. Adeyemo M.A., Spiegel B., Chang L. Meta-analysis: do irritable bowel syndrome symptoms vary between men and women?. Aliment Pharmacol Ther 2010, 32:738-755.
6. Herman J., Pokkunuri V., Braham L., et al. Gender distribution in irritable bowel syndrome is proportional to the severity of constipation relative to diarrhea. Gend Med 2010, 7:240-246.
7. Chey W.D., Kurlander J., Eswaran S. Irritable bowel syndrome - A clinical review. JAMA 2015, 109:949-957.
8. Meleine M., Matricon J. Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones. World J Gastroenterol 2014, 20:6725-6743.
9. Eswaran W., Goel A., Chey W.D. What role does wheat play in the symptoms of irritable bowel syndrome?. Gastroenterol Hepatol 2013, 9:85-91.
10. Posserud I., Ageforz P., Ekman R., et al. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 2004, 53:1102-1108.
11. Quigley E.M. Bacterial flora in irritable bowel syndrome: role in pathophysiology; implications for management. J Dig Dis 2007, 8:2-7.
12. Crowell M.D., Harris L., Jones M.P., et al. New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments. Curr Gastroenterol Rep 2005, 7:272-279.
13. Halland M., Saito Y. Irritable bowel syndrome; new and emerging treatments. BMJ 2015, 350:h1622.
14. Spiller R., Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil 2012, 3:258-268.
15. Wald A., VanThiel D.H., Hoechsttetter L., et al. Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology 1981, 80:1498-1500.
16. Shah S., Nathan L., Singh R., et al. E2 and not P4 increases NO release from NANC nerves of the gastrointestinal tract: implications in pregnancy. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1546-R1554.
17. Unruh A.M. Gender variations in clinical pain experience. Pain 1996, 65:123-167.
18. Papka R.E., Storey-Workley M. Estrogen receptor-alpha and -beta coexist in a subpopulation of sensory neurons of female rat dorsal root ganglia. Neurosci Lett 2002, 319:71-74.
19. Myers B., Schulkin J., Greenwood-Van Meerveld B. Sex steroids localized to the amygdala increase pain responses to visceral stimulation in rats. J Pain 2011, 12:486-494.
20. Chieng B.C., Christie M.J., Osborne P.B. Characterization of neurons in the rat central nucleus of the amygdala: cellular physiology, morphology and opioid sensitivity. J Comp Neurol 2006, 497:910-927.
21. Chang L., Mayer E.A., Labus J.S., et al. Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am J Physiol Regul Integr Comp Physiol 2006, 291:R277-R284.
22. Whitehead W., Cheskin L.J., Heller B.R., et al. Evidence of exacerbation of irritable bowel syndrome during menses. Gastroenterology 1990, 98:1485-1489.
23. Houghton L., Jackson N.A., Whorwell P.J., et al. Do male sex hormones protect from irritable bowel syndrome?. Am J Gastroenterol 2000, 95:2296-2300.
24. Berman S.M., Naliboff B.D., Chang L., et al. Enhanced preattentive central nervous system reactivity in irritable bowel syndrome. Am J Gastroenterol 2002, 97:2791-2797.
25. Berkley K.J. Sex differences in pain. Behav Brain Sci 1997, 20:371-380. [discussion: 435-513].
26. Fillingim R.M., Maixner W., Kincaid S., et al. Sex differences in temporal summation but not sensory-discriminative processing of thermal pain. Pain 1998, 75:121-127.
27. Naliboff B.D., Berman S., Chang L., et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003, 124:1738-1747.
28. Fukudo S., Kanazawa M., Mizuno T., et al. Impact of serotonin transporter-gene polymorphism on brain activation by colorectal distention. Neuroimage 2009, 47:946-951.
29. Labus J., Gupta A., Coveleskie K., et al. Sex differences in emotion-related cognitive processes in irritable bowel syndrome and healthy control subjects. Pain 2013, 154:2088-2099.
30. Alonso C., Guilarte M., Vicario M., et al. Maladaptive intestinal epithelial responses to life stress may predispose healthy women to gut mucosal inflammation. Gastroenterology 2008, 135:163-172.e1.
31. Enmark E., Pelto-Huikko M., Grandien K., et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997, 82:4258-4265.
32. Homma H., Hu E., Xu D.Z., et al. The female intestine is more resistant than the male intestine to gut injury and inflammation when subjected to conditions associated with shock states. Am J Physiol Gastrointest Liver Physiol 2005, 288:G466-G472.
33. Looijer-van Langen M., Hotte N., Dieleman L.A., et al. Estrogen receptor-β signaling modulates epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2011, 300:G621-G626.
34. Cremon C., Gargano L., Morselli-Labate A.M., et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009, 104:392-400.
35. Toner Q.B., Akman D. Gender role and irritable bowel syndrome: literature review and hypothesis. Am J Gastroenterol 2000, 95:11-16.
36. Cheney A.M. "Most girls want to be skinny": body (dis)satisfaction among ethnically diverse women. Qual Health Res 2011, 21:1347-1359.
37. Jack D.C. Silencing the self: women and depression 1991, Harvard University Press, Cambridge (MA).
38. Ali A., Toner B.B., Stuckless N., et al. Emotional abuse, self-blame, and self-silencing in women with irritable bowel syndrome. Psychosom Med 2000, 62:76-82.
39. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
40. Saad R.J., Rao S.S., Koch K.L., et al. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol 2010, 105(2):403-411.
41. Lewis S.J., Heaton K.W. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997, 32:920-924.
42. Ringel Y., Williams R.E., Kalilani L., et al. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009, 7:68-72.
43. Tuteja A.K., Talley N.J., Joos S.K., et al. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders. Am J Gastroenterol 2008, 103:1241-1248.
44. Ratuapli S.K., Bharucha A.E., Noelting J., et al. Phenotypic identification and classification of functional defecatory disorders using high-resolution anorectal manometry. Gastroenterology 2013, 144(2):314-322.e2.
45. Wald A., Bharucha A.E., Cosman B.C., et al. ACG clinical guidelines: management of benign anorectal disorders. Am J Gastroenterol 2014, 109:1141-1157.
46. Chey W.D., Baker J.R.B., Shifferd J. Assessment of abdominal symptoms before and after biofeedback therapy in patients with dyssynergic defecation. Am J Gastroenterol 2012, 107(Suppl 1):S718.
47. Davis D.M., Marcet J.E., Frattini J.C., et al. Is it time to lower the recommended screening age for colorectal cancer?. J Am Coll Surg 2011, 213:352.
48. Torre L.A., Bray F., Siegel R.L., et al. Global cancer statistics. CA Cancer J Clin 2012, 2015(65):87.
49. Power A.M., Talley N.J., Ford A.C. Association between constipation and colorectal cancer: systematic review and meta-analysis of observational studies. Am J Gastroenterol 2013, 108(6):894-903.
50. Rönnblom A., Holmström T., Tanghöj H., et al. Celiac disease, collagenous sprue and microscopic colitis in IBD. Observations from a population-based cohort of IBD (ICURE). Scand J Gastroenterol 2015, 50:1234-1240.
51. Brandt L.J., Chey W.D., Foxx-Orenstein A.E., American College of Gastroenterology Task Force on Irritable Bowel Syndrome, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009, 104(Suppl 1):S1-S35.
52. Chow M.A., Lebwohl B., Reilly N.R., et al. Immunoglobulin A deficiency in celiac disease. J Clin Gastroenterol 2012, 46(10):850-854.
53. Oxentenko A.S., Murray J.A. Ten things every gastroenterologist should know. Clin Gastroenterol Hepatol 2015, 13:1396-1404.
54. Macaigne G., Lahmek P., Locher C., et al. Microscopic colitis or functional bowel disease with diarrhea: a French prospective multicenter study. Am J Gastroenterol 2014, 109:1461-1470.
55. Chey W.D., Nojkov B., Rubenstein J.H., et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol 2010, 105:859-865.
56. Menees S.B., Kurlander J., Goel A., et al. Meta-analysis of the utility of common serum and fecal biomarkers in adults with IBS. Gastroenterology 2014, 146:S194.
57. Yang Z., Clark N., Park K.T. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol 2014, 12:253-262.
58. Wedlake L., A'Hern R., Russell D., et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009, 30:707-717.
59. Pimentel M., Morales W., Rezaie A., et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One 2015, 10(5):e0126438. eCollection 2015.
60. Lackner J.M., Ma C.X., Keefer L., et al. Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013, 11(9):1147-1157.
61. Brown J., Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev 2014, (3). Cd009590.
62. Seaman H.E., Ballard K.D., Wright J.T., et al. Endometriosis and its coexistence with irritable bowel syndrome and pelvic inflammatory disease: findings from a national case-control study-Part 2. BJOG 2008, 115:1392-1396.
63. Drossman D.A., Thompson W.G. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med 1992, 116:1009-1016.
64. Ricci J., Jhingran P., Harris W., et al. Impact of differences in severity of irritable bowel syndrome (IBS) on patient's well-being and resource use. Gastroenterology 2001, 120:A406.
65. Luttecke K.A. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin 1980, 6:437-443.
66. Coffin B., Dapoigny M., Cloarec D., et al. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2004, 28:11-15.
67. Lembo A., Ameen V.Z., Drossman D. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005, 3:717-725.
68. Drossman D.A. 2012 David Sun lecture: helping your patient by helping yourself - how to improve the patient-physician relationship by optimizing communication skills. Am J Gastroenterol 2013, 108:521-528.
69. Drossman D.A. Multi-dimensional clinical profile (MDCP) for the functional gastrointestinal disorders 2015, 3-14. The Rome Foundations, Raleigh (NC).
70. Cuomo R., Andreozzi P., Zito F.P., et al. Irritable bowel syndrome and food interaction. World J Gastroenterol 2014, 20:8837-8845.
71. Posserud I., Strid H., Störsrud S., et al. Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls. United European Gastroenterol J 2013, 1:358-367.
72. Shekhar P.J., Monaghan C., Morris J., et al. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization regulated by serotonin. Gastroenterology 2013, 145:749-757.
73. Hayes P., Corish C., O'Mahony E., et al. A dietary survey of patients with irritable bowel syndrome. J Hum Nutr Diet 2014, 27(Suppl 2):36-47.
74. Heizer W.D., Southern S., McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc 2009, 109:1204-1214.
75. Wouters M.M. Histamine antagonism and postinflammatory visceral hypersensitivity. Gut 2014, 63:1836-1837.
76. Kelly J.R., Kennedy P.J., Cryan J.F., et al. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci 2015, 9:392.
77. Ford A.C., Moayyedi P., Lacy B.E., et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014, 109(Suppl 1):S2-S26.
78. Fritscher-Ravens A., Schuppan D., Ellrichmann M., et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 2014, 147:1012-1020.e1014.
79. Rostami K. From microenteropathy to villous atrophy: what is treatable?. Dig Liver Dis 2003, 35:758-759.
80. Guo Y.B., Khuang K.-M., Kuang L., et al. Association between diet and lifestyle habits and irritable bowel syndrome: a case-control study. Gut Liver 2015, 9:649-656.
81. Vazquez-Roque M.I., Camilleri M., Smyrk T., et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013, 144:903-911.e3.
82. Biesiekierski J.R., Newnham E.D., Irving P.M., et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011, 106:508-514.
83. Sollid L.M., Markussen G., Ek J., et al. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med 1989, 169:345-350.
84. Bizzaro N., Tozzoli R., Villalta D., et al. Cutting-edge issues in celiac disease and in gluten intolerance. Clin Rev Allergy Immunol 2012, 42:279-287.
85. Ludvigsson J.F., Leffler D.A., Bai J., et al. The Oslo definitions for coeliac disease and related terms. Gut 2013, 62:43-52.
86. Di Sabatino A., Corazza G.R. Nonceliac gluten sensitivity: sense or sensibility?. Ann Intern Med 2012, 156:309-311.
87. Junker Y., Zeissig S., Kim S.J., et al. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med 2012, 209:2395-2408.
88. Biesiekierski J.R., Peters S.L., Newnham E.D., et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013, 145:320-328.e1-3.
89. Rodrigo L., Blanco I., Bobes J., et al. Effect of one year of a gluten-free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case-control study. Arthritis Res Ther 2014, 16:421103.
90. Murray K., Wilkinson-Smith V., Hoad C., et al. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol 2014, 109:110-119.
91. Halmos E.P., Power V.A., Shepherd S.J., et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014, 146:67-75.e5.
92. Ong D.K., Mitchell S.B., Barrett J.S., et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010, 25:1366-1373.
93. Staudacher H.M., Lomer M.C.E., Anderson J.L., et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012, 142:1510-1518.
94. Moayyedi P., Quigley E.M., Lacy B.E., et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2014, 109:1367-1374.
95. Song B.K., Cho K.O., Jo Y., et al. Colon transit time according to physical activity level in adults. J Neurogastroenterol Motil 2012, 18:64-69.
96. Johannesson E., Simren M., Strid H., et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011, 106:915-922.
97. Palermo T.M., Law E., Churchill S.S., et al. Longitudinal course and impact of insomnia symptoms in adolescents with and without chronic pain. J Pain 2012, 13:1099-1106.
98. Jarrett M., Heitkemper M., Cain K.C., et al. Sleep disturbance influences gastrointestinal symptoms in women with irritable bowel syndrome. Dig Dis Sci 2000, 45:952-959.
99. Buchanan D.T., Cain K., Heitkemper M., et al. Sleep measures predict next-day symptoms in women with irritable bowel syndrome. J Clin Sleep Med 2014, 10:1003-1009.
100. ®)-a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013, 163:65-72.
101. Madisch A., Holtmann G., Plein K., et al. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004, 19:271-279.
102. Rozza A.L., Meira de Faria F., Souza Brito A.R., et al. The gastroprotective effect of menthol: involvement of anti-apoptotic, antioxidant and anti-inflammatory activities. PLoS One 2014, 9:1-6.
103. Khanna R., MacDonald J., Levesque B. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2014, 48:505-512.
104. Merat S., Khalili S., Mostajabi P., et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010, 55:1385-1390.
105. Cash B.D., Epstein M.S., Shah S.M. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci 2015, 61(2):560-571.
106. Imai H., Osawa K., Yasuda H., et al. Inhibition by the essential oils of peppermint and spearmint of the growth of pathogenic bacteria. Microbios 2001, 106(Suppl 1):31-39.
107. Ford A.C., Quigley E.M., Lacy B.E., et al. Efficacy of prebiotics, probiotics and synbiotics in irritable bowel syndrome and chronic idiopathic constipation systematic review and meta-analysis. Am J Gastroenterol 2014, 109:1547-1561.
108. Whorwell P.J., Altringer L., Morel J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101:1581-1590.
109. Sinn D.H., Song J.H., Kim H.J., et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008, 53:2714-2718.
110. Menees S., Maneerattannaporn M., Kim H.M., et al. Efficacy of rifaximin in patients with irritable bowel syndrome: a meta-analysis. Am J Gastroenterol 2012, 107:28-35.
111. Pimentel M., Lembo A., Chey W.D., et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011, 364:22-32.
112. FDA approves 2 therapies to treat IBS-D. Available at: . Accessed February 11, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm448328.htm.
113. Jailwala J., Imperiale T.F., Kroenke K., et al. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000, 133:136-147.
114. Ford A.C., Talley N.J., Spiegel B.M., et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008, 337:a2313.
115. Bajor A., Tomblom H., Rudling M., et al. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 2015, 6:84-92.
116. Camilleri M., Acosta A., Busciglio I., et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2015, 41(5):438-448.
117. Walters J.R., Johnston I.M., Nolan J.D., et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 2015, 41(1):54-64.
118. Camilleri M., Mayer E.A., Drossman D.A., et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999, 13:1149-1159.
119. Garsed K., Chernova J., Hastings M., et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014, 63:1617-1625.
120. Dove L.S., Lembo A., Randall C.W., et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 2013, 145(2):329-338.
121. Awad R.A., Camacho S. A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. Colorectal Dis 2010, 12:1131-1138.
122. Chapman R.W., Stanghellini V., Geraint M., et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013, 108:1508-1515.
123. Ironwood reports positive top-line results from phase III trial of 72 mcg linaclotide in adults with chronic idiopathic constipation. Available at: . Accessed May 11, 2015. http://investor.ironwoodpharma.com/releasedetail.cfm?ReleaseID=936437.
124. Castro J., Harrington A.M., Hughes P.A., et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. Gastroenterology 2015, 145:1334-1346.
125. Rao S., Lembo A.J., Shiff S.J., et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012, 11:1714-1724.
126. Drossman D.A., Chey W.D., Johanson J.F., et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009, 29:329-341.
127. Shin A., Camilleri M., Kolar G., et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014, 39:239-253.
128. Mendzelevski B., Ausma J., Chanter D.O., et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol 2012, 73:203-209.
129. Ford A.C., Quigley E.M., Lacy B.E., et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014, 109:1350-1365.
130. Drossman D.A. Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol 2009, 104:2897-2902.